Transplantation of Adipose Tissue Lacking Leptin Is Unable to Reverse the Metabolic Abnormalities Associated With Lipoatrophy
- Carlo Colombo1,
- Jaime J. Cutson1,
- Toshimasa Yamauchi2,
- Charles Vinson3,
- Takashi Kadowaki2,
- Oksana Gavrilova1 and
- Marc L. Reitman1
- 1Diabetes Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland
- 2Department of Internal Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
- 3Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
Abstract
Severe adipose tissue deficiency (lipoatrophy) causes insulin-resistant diabetes, elevated serum triglyceride and fatty acid levels, and massive triglyceride deposition in the liver. In lipoatrophic A-ZIP/F-1 mice, transplantation of normal adipose tissue greatly improved these parameters, whereas 1 week of leptin infusion had more modest effects. In contrast, leptin infusion was strikingly more effective in the aP2-n sterol response element binding protein 1 lipoatrophic mouse. Here we show that a longer duration of leptin infusion further improves the metabolic status of the A-ZIP/F-1 mice and that genetic background does not make a major contribution to the effect of leptin on glucose and insulin levels. Adipose transplantation using leptin-deficient ob/ob fat had no effect on the phenotype of the A-ZIP/F-1 mice. Moreover, the presence of ob/ob adipose tissue did not enhance the effects of leptin infusion. Serum adiponectin levels were 2% of control levels in the A-ZIP/F-1 mouse and increased only twofold with adipose transplantation and not at all after leptin infusion, suggesting that adiponectin deficiency is not a major contributor to the diabetic phenotype. Taken together, these results suggest that sequestration of triglycerides into fat may not be enough to restore a nondiabetic phenotype and that leptin deficiency plays a major role in causing the metabolic complications of lipoatrophy.
Footnotes
-
Address correspondence and reprint requests to Marc Reitman, Merck Research Laboratories, P.O. Box 2000, RY80M-213, Rahway, NJ 07065-0900. E-mail: marc_reitman{at}merck.com.
Received for publication 29 April 2002 and accepted in revised form 22 May 2002.
M.L.R. is currently employed by Merck.
PPAR, peroxisome proliferator-activated receptor; SREBP-1, sterol response element binding protein 1; WAT, white adipose tissue.
- DIABETES














